Current Location:home > Detailed Browse
Article Detail
Effective Treatment of Severe COVID-19 Patients with Tocilizumab
Abstracts
| Background: In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China, which spread rapidly and has become a world-wide public health challenge. We aimed to assess the efficacy of tocilizumab in severe patients with Corona Virus Disease-19 (COVID-19) and seek a new therapeutic strategy. Methods: The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People’s Hospital were given tocilizumab in addition to routine therapy between February 5 and February 14, 2020. The changes of clinical manifestations, CT scan image, and laboratory examinations were retrospectively analyzed. Findings: Within a few days, the fever returned to normal and all other symptoms improved remarkably. Fifteen of the 20 patients (75.0%) had lowered their oxygen intake and one patient need no oxygen therapy. CT scans manifested that the lung lesion opacity absorbed in 19 patients (90.5%). The percentage of lymphocytes in peripheral blood, which decreased in 85.0% patients (17/20) before treatment (mean, 15.52 ± 8.89%), returned to normal in 52.6% patients (10/19) on the fifth day after treatment. Abnormally elevated C-reactive protein decreased significantly in 84.2% patients (16/19). No obvious adverse reactions were observed. Nineteen patients (90.5%) have been discharged on average 13.5 days after the treatment with tocilizumab and the rest are recovering well. Interpretation: Tocilizumab is an effective treatment in severe patients of COVID-19, which provided a new therapeutic strategy for this fatal infectious disease. |
Download
Comment
From:
魏海明
Subject:
Medicine, Pharmacy
>>
Clinical Medicine
DOI：10.12074/202003.00026
Cite as:
chinaXiv:202003.00026
(or this versionchinaXiv:202003.00026V1)
Recommended references：
Xu, Xiaoling,Han, Mingfeng,Li, Tiantian,Sun, Wei,Wang, Dongsheng,Fu, Binqing,Zhou, Yonggang,Zheng, Xiaohu,Yang, Yun,Li, Xiuyong,Zhang, Xiaohua,Pan, Aijun,Wei, Haiming.(2020).Effective Treatment of Severe COVID-19 Patients with Tocilizumab.[ChinaXiv:202003.00026] (Click&Copy)
| Version History | ||||
|---|---|---|---|---|
| [V1] | 2020-03-05 16:04:07 | chinaXiv:202003.00026V1 | Download | |
| Related Paper |
|---|
1. 胡蜂毒对类风湿关节炎实验模型具有潜在的治疗作用 2020-05-05
3. Germline Polymorphisms and Length of Survival of Nasopharyngeal Carcinoma: An Exome-Wide Association Study in Multiple Cohorts 2020-03-06
5. Confirmed asymptomatic carrier of SARS-CoV-2 2020-02-28
6. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia 2020-02-28
7. 基于移动平均预测限预判新型冠状病毒感染疫情趋势与适时风险分级 2020-02-28
8. ACE2 shedding and furin abundance in target organs may influence the efficiency of SARS-CoV-2 entry 2020-02-27
Copyright@2016 National Science Library，Chinese Academy of Sciences Address:33 Beisihuan Xilu,Zhongguancun,Beijing P.R.China,100190
京ICP备05002861号-25